Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

Analysts on Wall Street project that PTC Therapeutics (PTCT) will announce quarterly loss of $0.96 per share in its forthcoming report, representing a decline of 300% year over year. Revenues are projected to reach $252.51 million, declining 17.8% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.With that in mind, let's delve into the average projections of some PTC Therapeutics metrics that are commonly tracked and projected by analysts on Wall Street.The combined assessment of analysts suggests that 'Revenues- Net product revenue' will likely reach $141.85 million. The estimate points to a change of -8.5% from the year-ago quarter.Analysts predict that the 'Revenues- Royalty revenue' will reach $73.16 million. The estimate points to a change of +43.4% from the year-ago quarter.Based on the collective assessment of analysts, 'Revenues- Net product revenue- Emflaza' should arrive at $50.95 million. The estimate indicates a year-over-year change of -24.4%.It is projected by analysts that the 'Revenues- Net product revenue- Translarna' will reach $78.77 million. The estimate points to a change of +4.8% from the year-ago quarter.View all Key Company Metrics for PTC Therapeutics here>>>PTC Therapeutics shares have witnessed a change of +9.1% in the past month, in contrast to the Zacks S&P 500 composite's -0.5% move. With a Zacks Rank #3 (Hold), PTCT is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Just Released: Zacks Top 10 Stocks for 2025Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential. See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report PTC Therapeutics, Inc. (PTCT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks